Skp1 is an essential adaptor protein of the Skp1-Cul1-F-box protein complex and is able to stabilize the conformation of some ubiquitin E3 ligases. However, the role Skp1 plays during tumorigenesis remains unclear and Skp1-targeting agent is lacking. Here we showed that Skp1 was overexpressed in 36/64 (56.3%) of non-small cell lung cancers, and elevated Skp1 was associated with poor prognosis. By structure-based high-throughput virtual screening, we found some Skp1-targeting molecules including a natural compound 6-O-angeloylplenolin (6-OAP). 6-OAP bound Skp1 at sites critical to Skp1-Skp2 interaction, leading to dissociation and proteolysis of oncogenic E3 ligases NIPA, Skp2, and β-TRCP, and accumulation of their substrates Cyclin B1, P27 and E-Cadherin. 6-OAP induced prometaphase arrest and exerted potent anti-lung cancer activity in two murine models and showed low adverse effect. These results indicate that Skp1 is critical to lung cancer pathogenesis, and Skp1 inhibitor inactivates crucial oncogenic E3 ligases and exhibits significant therapeutic potentials.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741501PMC
http://dx.doi.org/10.18632/oncotarget.5547DOI Listing

Publication Analysis

Top Keywords

skp1
8
lung cancer
8
oncogenic ligases
8
skp1 lung
4
cancer clinical
4
clinical significance
4
significance therapeutic
4
therapeutic efficacy
4
efficacy small
4
small molecule
4

Similar Publications

Clinical and experimental studies have demonstrated that type 2 diabetes mellitus (T2DM) affects the brain structure and function, in particular the hippocampus, leading to cognitive impairments. However, the molecular mechanisms underlying cognitive deficits induced by T2DM are not fully understood. In this study, we aimed to investigate the effects of T2DM on behavior, the proteome profile in the hippocampus, and the potential molecular pathways involved in the development of cognitive dysfunction in T2DM mice.

View Article and Find Full Text PDF

is an important plant germplasm resource, rich in nutrients and possessing unique medicinal value. However, due to its small floral organs, low seed setting rate of a single flower, high cost of artificial emasculation, and artificial pollination, the use of male sterile lines to prepare hybrids has become a common choice. In this study, var.

View Article and Find Full Text PDF

Hypoxic and acidic tumor microenvironment-driven AVL9 promotes chemoresistance of pancreatic ductal adenocarcinoma via the AVL9-IκBα-SKP1 complex.

Gastroenterology

November 2024

Pancreas Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, PR China. Electronic address:

Article Synopsis
  • Gemcitabine combined with albumin-paclitaxel (AG) is an important treatment for pancreatic ductal adenocarcinoma (PDAC), but resistance to chemotherapy is a major issue, driving this study to uncover ways to improve AG effectiveness.
  • Researchers used various models, including organoids and patient-derived xenografts, along with several analytical techniques to investigate the mechanisms causing AG resistance, identifying a key target called AVL9.
  • The study found that AVL9 is upregulated by the hypoxia-related factor HIF-1α and activates the NF-κB pathway, leading to cancer progression; the inhibitor Edotecarin shows potential in reducing AG resistance in PDAC, suggesting a new approach to enhance treatment
View Article and Find Full Text PDF
Article Synopsis
  • Inflammatory bowel disease (IBD) poses a significant health risk, including an increased chance of developing colorectal cancer (CRC), but understanding and treatment options are still limited.
  • This study identifies FBXO22, a protein that helps regulate cellular processes, as a key player in inhibiting inflammation and CRC by promoting the degradation of a specific form of mTOR, which is involved in cancer signaling.
  • Treatment with the mTOR inhibitor rapamycin shows promise in reducing colorectal inflammation and cancer effects, highlighting the potential role of FBXO22 and mTOR pathways in colorectal disease management.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!